Navigation Links
Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
Date:11/4/2010

provided in such response may not satisfy the FDA; the FDA may request additional information prior to approval; unexpected new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner Arena or others expect or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from Arena's collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Contact: Arena Pharmaceuticals, Inc.

Media Contact: Russo PartnersJack Lief

David Schull, PresidentPresident and CEO

david.schull@russopartnersllc.com212.845.4271Cindy McGeeManager, IR and Corporate Communications

Anthony J. Russo, Ph.D., CEO858.453.7200, ext. 1479

tony.russo@russopartnersllc.com212.845.425
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
2. Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
3. Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
4. Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
5. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
6. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
7. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
9. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
10. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
11. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014  Decision Resources Group finds ... Brazil and ... and commonly prescribe long-acting beta-agonist (LABA)- and long-acting ... so within current severe cost/coverage constraints. Therefore, new ... expected to launch in these countries—which will considerably ...
(Date:8/21/2014)... MISSION, Kan. , Aug. 21, 2014 /PRNewswire-iReach/ ... Information Trust Alliance (HITRUST) under its Common Security ... ScriptPro,s Enterprise Security and Privacy Manager, "We appreciate ... the level of commitment that this certification signifies. ... compliant." ABOUT THE CSF CERTIFICATION PROCESS: ...
(Date:8/21/2014)... , August 21, 2014 ... BreedIT Ltd., the exclusive worldwide license holder and ... plant breeders and researchers, today is pleased to ... venture with Seach Ltd, a leading Israeli medical ... research and develop new breeds of medical Cannabis ...
Breaking Medicine Technology:Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3ScriptPro Achieves HITRUST Certification 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4
... 26 Paratek Pharmaceuticals, Inc. today,announced positive Phase ... a first-in-class aminomethylcycline (AMC). The Phase 2 study ... forms of PTK 0796 to,Zyvox(R) in the treatment ... (cSSSIs). Paratek,s trial met its primary safety and,tolerability ...
... affirmed the clinical benefits of,ACTEMRA -, NUTLEY, ... III studies,showed that patients who suffer from the ... significant improvements in signs and,symptoms when treated with ... with methotrexate alone. The final results of,both studies ...
Cached Medicine Technology:Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 2ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 3ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 4ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 5ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 6
(Date:8/22/2014)... August 22, 2014 Until now, those with ... crutches or walkers to keep mobile. Thanks to an inventor ... much more effective. , He developed a prototype for the ... injured leg or foot but provide comfort and reduce pain ... different heights, it is also convenient and easy to install ...
(Date:8/22/2014)... a wide range of epigenetic changesalterations in DNA across the ... with Crohn,s disease (CD), reports Inflammatory Bowel Diseases ... Foundation of America (CCFA). The journal is published ... Wolters Kluwer Health . , The study ... of the genome in children with CD, according to Professor ...
(Date:8/22/2014)... lymphoma will be able to better understand their risks ... premature menopause with different treatments. , The findings, set ... Institute , are based on the experience of more ... for the cancer over a period of more than ... with Hodgkin lymphoma who receive certain types of chemotherapy ...
(Date:8/22/2014)... Watertown, MA (PRWEB) August 22, 2014 ... Health (IFNH) at Rutgers, the State University of ... , an innovative children’s media organization, to educate young ... that will build on the strengths of both organizations. ... ChopChop Magazine, a health communications fellowship program, and video ...
(Date:8/22/2014)... Ticket Down is a reliable source for cheap ... Rentschler Field. There has never been a better time to be ... After the strong showing at the 2014 World Cup in Brazil, ... featured in large stadiums around the country. Since the World Cup ... some of the best club teams in the sport played on ...
Breaking Medicine News(10 mins):Health News:Assistive Device for Walking Invented by InventHelp Client (VBL-501) 2Health News:Study shows epigenetic changes in children with Crohn's disease 2Health News:Scientists map risk of premature menopause after cancer treatment 2Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 2Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 3Health News:USA vs. Ecuador Tickets: Ticket Down Slashes USA (USMT) vs. Ecuador Tickets at Rentschler Field in East Hartford on Oct. 10th 2Health News:USA vs. Ecuador Tickets: Ticket Down Slashes USA (USMT) vs. Ecuador Tickets at Rentschler Field in East Hartford on Oct. 10th 3
... INDIANAPOLIS, July 1 CoLucid Pharmaceuticals, Inc., ... central nervous,system disorders, announced it closed a ... Capital led the round, which included previous ... Funds and,Triathlon Medical Ventures. The financing will ...
... Conn., July 1 The organic food that ... intended and often,contains more nutrients than its counterpart., ... the popularity of organic food on the rise, ... more accessible than ever., "The difference between ...
... USB duplicator with copy protection and digital rights management features available ... Only partitions, Autorun support, copy and paste restriction and document printing ... ... (PRWEB) July 1, 2008 -- Nexcopy Inc., a leading manufacturer in ...
... can be overwhelming; Allsup provides tips on getting prepared to file ... ... Every day, people across the United States must stop working because ... challenges when faced with these circumstances can be overwhelming, including where ...
... Researchers have developed a series of tests that for the ... and smell (olfactory function) in young children, according to a ... Otolaryngology Head and Neck Surgery . , The study, ... 5-7 can identify a majority of 16 different test odorants ...
... showing that psilocybin, a substance contained in "sacred mushrooms," ... that those beneficial effects appear to last more than ... of Psychopharmacology , the Johns Hopkins researchers note that ... controlled conditions in a Hopkins study published in 2006, ...
Cached Medicine News:Health News:CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound 2Health News:CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound 3Health News:CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound 4Health News:Figure Skater Peggy Fleming Teams With HealthSaver: Go Organic for Quality, Natural Food 2Health News:Figure Skater Peggy Fleming Teams With HealthSaver: Go Organic for Quality, Natural Food 3Health News:Figure Skater Peggy Fleming Teams With HealthSaver: Go Organic for Quality, Natural Food 4Health News:World's First USB Duplicator with Copy Protection and Digital Rights Management Available from Nexcopy and TrusCont Ltd. 2Health News:World's First USB Duplicator with Copy Protection and Digital Rights Management Available from Nexcopy and TrusCont Ltd. 3Health News:Two Categories of Information Are Key in Seeking SSDI Benefits 2Health News:Two Categories of Information Are Key in Seeking SSDI Benefits 3Health News:Two Categories of Information Are Key in Seeking SSDI Benefits 4Health News:Spiritual effects of hallucinogens persist, Johns Hopkins researchers report 2
55 DSL's new collection of optical frames has established a strong personality and developed,superficial retro concepts with contemporary styles and strong impacting colours....
... and highly sought-after, the ... collection of sunglasses and ... the very latest men's ... timeless sources of inspiration ...
... Extended Ablation laser enables the physician to provide ... results and no downtime., The new Whisper NG ... an extra long pulse width to achieve "Extended ... over 3-5 days, and occurs simultaneously with the ...
... the art software package designed to assist in ... by a lens manufacturer with years of experience ... is designed to help you run your lab ... the software dictates., ,Designed specifically for integrated retail ...
Medicine Products: